Lear Corporation (NYSE:LEA)
Lear Corporation (NYSE:LEA), ended its previous trading session at $166.73 showing a gain of 3.03999999999999 or 1.86 percent with respect to the price of $163.69 when stock market opened. The company traded 430741 shares over the course of the trading day. Giving the average volume of 435.15 Million over the course of 3 consecutive months. Which signifies a pretty good change over the time with its shares outstanding of 60.16 Million.
Lear Corporation (NYSE:LEA) is currently trading Higher than its price target which is set to $163.61 by the analyst. The stock is -2.22% Below its 1-Year High which is $170.51. LEA has a difference of 163.81% from its 1 year low which stands at $63.20. The company is currently rated by analyst who are keeping a close eye on the stock as 2.2. Where 1 means Buy, 2.5 meaning Hold and 5 as Sell.
Lear Corporation (NYSE:LEA) Performance Snapshot
The stock performed exceptionally bad in the previous week which depicts an decrease of 4.1 percent in the shares price. The company added about 6.68% in its share price over 1-Month. While taking about the performance of the stock over 1-year interval is 22.39 Percent. LEA currently shows 4.84% as its year to date performance.
Lear Corporation (NYSE:LEA) Price Insight
The stock needs to grow about $-3.11999999999998 to reach its price target. In order to seek the stock’s directional movements, 20-Days, 50 Days and 200-Days moving averages are 3.64%, 12.1% and 40.04 percent respectively. The stock trades about 1.44 percent of its Float giving its total shares Outstanding are 60.16 Million. LEA gained about 53.26 percent in 6 months showing its Average True Range of 4.52. The company currently has a RSI and Beta of 61.89 and 1.59.
While talking about Lear Corporation (NYSE:LEA) valuation ratios, the stock trades with a P/S and P/B of 0.62 and 2.43 which is significantly better and attractive as compared to its peers.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)
Performance Indicators of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Analytical Review